Cellectis Provides Business Objectives for 2022 and Updates its Corporate Presentation

Written by Customer Service on January 4, 2022. Posted in Public Companies.

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, reported business objectives for its products pipeline and in-house manufacturing for 2022. “In 2022 we will be focusing on pursuing recruitments into our core ongoing clinical trials BALLI-01, AMELI-01, MELANI-01 and on filing an investigational new drug application (IND) for the first dual allogeneic UCART20x22,” said Dr André Choulika, CEO of Cellectis. “Furthermore, we are on-track to start dosing patients with our in-house manufactured investigational medicinal products (IMPs) during 2022. Our two manufacturing sites in Raleigh, NC and Paris, France are now fully operational. This focus allows us...

ORIC Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

Written by Customer Service on January 4, 2022. Posted in Public Companies.

SOUTH SAN FRANCISCO and SAN DIEGO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive officer, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 3:00 p.m. ET. A live webcast of the company presentation will be available through the investor section of the company’s website at www.oricpharma.com. A replay of the webcast will be available for 30 days following the event. About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product...

Meritage Homes Fourth Quarter 2021 Earnings Conference Call and Webcast Scheduled for January 27, 2022

Written by Customer Service on January 4, 2022. Posted in Public Companies.

SCOTTSDALE, Ariz., Jan. 04, 2022 (GLOBE NEWSWIRE) — Meritage Homes Corporation (NYSE: MTH), a leading U.S. homebuilder, plans to release the Company’s fourth quarter 2021 results on Wednesday, January 26, 2022 after the market closes. Management will host a conference call to discuss the results at 8:00 a.m. Mountain Standard Time (10:00 a.m. Eastern Standard Time) on Thursday, January 27, 2022. The call will be webcast with an accompanying slideshow, both available on the “Investor Relations” page of the Company’s website at https://investors.meritagehomes.com. A live webcast of the conference call will be available online at https://investors.meritagehomes.com. Telephone participants will be able to join by dialing in to 1-877-407-6951 US toll free or 1-412-902-0046 on the day of the call. A replay of...

Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer

Written by Customer Service on January 4, 2022. Posted in Public Companies.

SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately. Dr. Inrig brings to Travere more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution and global regulatory engagement. Dr. Inrig joins the Company as it prepares for accelerated approval submissions of sparsentan for IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) in 2022, as well as the continued advancement of its pegtibatinase program in classical homocystinuria (HCU). “We are excited to welcome Jula to the Travere Therapeutics team,” said Eric Dube, Ph.D., chief executive officer of Travere Therapeutics. “Jula has a clear passion for championing positive advancements...

iBio Announces Participation in the H.C. Wainwright BioConnect Conference

Written by Customer Service on January 4, 2022. Posted in Public Companies.

BRYAN, Texas, Jan. 04, 2022 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that it will participate in the H.C. Wainwright BioConnect Conference, to be held virtually January 10-13, 2022. iBio’s pre-recorded presentation will be available on demand during the event for all registered attendees. Beginning on Monday, January 10, 2022, the presentation will also be available on the Company’s website at www.ibioinc.com under “News & Events” in the Investors section. About iBio, Inc. iBio is a developer of next-generation biopharmaceuticals and a pioneer in sustainable, plant-based biologics manufacturing. Its FastPharming System® combines...

Atreca to Present Anti-SARS-CoV-2 Antibody Discoveries at Keystone Symposia Conference: Antibodies as Drugs

Written by Customer Service on January 4, 2022. Posted in Public Companies.

SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present data on broadly neutralizing SARS-CoV-2 antibodies discovered by the company at the upcoming Keystone Symposia Conference: Antibodies as Drugs, being held January 30 – February 2, 2022 both in Keystone, Colo. and virtually. Details are as follows: Abstract title: Broadly neutralizing SARS-CoV-2 antibodies discovered in multiple patients target the Receptor Binding Domain Poster Session 1: January 31, 10:00 a.m. – 7:30 p.m. ET The abstract is currently available to registered attendees on the Keystone Symposia website,...

Century Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Written by Customer Service on January 4, 2022. Posted in Public Companies.

PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 1:30 PM ET. A live webcast of the event will be available on the “Events & Presentations” page in the “Investors” section of the Company’s website at https://investors.centurytx.com/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 30 days following the presentation. About Century Therapeutics Century Therapeutics, Inc. (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell...

World Insurance Associates Acquires Livingston Insurance Agency

Written by Customer Service on January 4, 2022. Posted in Mergers And Acquisitions.

Tinton Falls, NJ, Jan. 04, 2022 (GLOBE NEWSWIRE) — World Insurance Associates LLC (“WIA”), a Top 100 Insurance Brokerage, announced today that it acquired Livingston Insurance Agency (“Livingston”) on December 31, 2021. Terms of the transaction were not disclosed. Livingston was founded in 1991. Today, they provide personal insurance–home, auto, umbrella, flood, and boat insurance –to name a few of the many coverages they offer. In addition, they provide business insurance, offering a wide range of coverages to suit their clients’ commercial needs. “We endeavor to obtain and service all of our client’s insurance needs. We work together as a team to provide the best expert advice possible to ensure quality coverage,” said Robert Peason, Principal and CFO, Livingston Insurance Agency. “As part of World, we will continue to...

Mettler-Toledo International Inc. Announces Webcast of Presentation at the Virtual 40th Annual J.P. Morgan Healthcare Conference

Written by Customer Service on January 4, 2022. Posted in Public Companies.

Columbus, OH, Jan. 04, 2022 (GLOBE NEWSWIRE) — Mettler-Toledo International Inc. (NYSE:MTD) today announced the webcast of its presentation at the Virtual 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 9:45 a.m Eastern Time. To hear a live webcast of the presentation, visit the investor relations page on the Company’s Web site at www.mt.com/investors. A replay of the webcast will be available for seven days. METTLER TOLEDO (NYSE: MTD) is a leading global supplier of precision instruments and services. We have strong leadership positions in all of our businesses and believe we hold global number-one market positions in most of them. We are recognized as an innovation leader and our solutions are critical in key R&D, quality control, and manufacturing processes for customers in a wide...

Valley National Bancorp Receives Regulatory Approval for the Acquisition of Bank Leumi USA From the Federal Reserve Bank of New York and the Office of the Comptroller of the Currency

Written by Customer Service on January 4, 2022. Posted in Mergers And Acquisitions.

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) — Valley National Bancorp (NASDAQ:VLY) (“Valley”) announced today it has received regulatory approval from the Federal Reserve Bank of New York and the Office of the Comptroller of the Currency to complete the previously announced acquisition of Bank Leumi Le-Israel Corporation, the US subsidiary of Bank Leumi Le-Israel B.M., and parent company of Bank Leumi USA. The acquisition remains subject to certain additional regulatory approvals, including by the New York State Department of Financial Services and the Bank of Israel, and other closing conditions, including approval by the shareholders of Valley. About ValleyAs the principal subsidiary of Valley National Bancorp, Valley National Bank is a regional bank with over $41 billion in assets. Valley is committed to giving people and businesses...

Day: January 4, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice